

SMi is launching its inaugural Immunogenicity Conference

This two day event is designed to enhance SMi's portfolio of pharmaceutical conferences, especially with a growing demand for biologic therapeutics.

LONDON, ENGLAND, February 24, 2014 /EINPresswire.com/ -- What stimulates an immune response? How does the system cope with immunogenic compounds? And how do you screen for potential problems?

The [Conference](#) will address all these concerns and enable Clinical Immunologists, Physicians and Specialists within the field of [Immunogenicity](#) to discuss the major challenges currently being faced within the pharmaceutical industry.

The focus is on pre-clinical analysis and assessing treatments for clinical development. It will endeavour to look at the assessment of early risks in immunogenicity and the evaluation of in silico tools for determining immunogenicity. With an insight into the safety, development and validation of Monoclonal Antibodies.

Immunogenicity is a hurdle one looks to overcome and with the likes of aggregation being a factor when handling proteins, key sessions on Immunomodulation and Inducing Immunological Tolerance will enable delegates to get an understanding of how to address this and improve probability and efficacy.

From a clinical perspective, the conference will assess consideration and design of biologic therapeutics, clinical implications and review what the clinical outcomes are from using these immune modulatory approaches.

The conference will also look at, how to benefit the patient by assessing efficacy and toxicological concerns alongside the management of immunogenic responses. With regulators supposing that animal studies are not good predictors – how can predictability be shown with pre-clinical in-vitro tools?

Business Benefits:

- Grasp an understanding of Immunogenicity and gain an insight into assessing early risks
- Hear case studies on the tools for consideration being utilised for the determination of immunogenicity
- Assess major hurdles in clinical development and the implications in design of biologic therapeutics
- Enhance your understanding on how to best evaluate read outs for immune response

Conference Chairs:

- Matthew Baker, Chief Scientific Officer, Antitope
- Martin Lechmann, Development DMPK Project Leader, Roche

Key Speakers include:

- Robert Dodge, Associate Director, BMS
- Thomas Lee, Scientific Investigator, Clinical Immunology, GSK
- Ronit Mazor, Research Fellow, National Cancer Institute, National Institutes of Health
- Anne De Groot, CEO/CSO, EpiVax Inc
- Daniel Kramer, Associate Director, Project Representative NBE, Merck Serono
- Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc.

For those interested in attending there is a £300 discount until the 28th of February. For more information visit the [website http://www.smi-online.co.uk/immuno10.asp](http://www.smi-online.co.uk/immuno10.asp) or contact Fateja Begum on +44 (0) 20 7827 6184 or email fbegum@smi-online.co.uk

Fateja Begum
SMi Group Ltd
+44 (0) 20 7827 6184
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/192105435>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.